BioSpace News Archive

Heart pump devices are essentially mechanical pumps playing the role of ventricular assist devices.

LYNPARZA ® (olaparib) Receives Three New Approvals in Japan Approvals in Three Types of Cancer Are Based on the PAOLA-1, PROfound and POLO Phase 3 Trials

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal year ended September 30, 2020. Christopher U Missling, PhD, Pres

Preclinical safety, long duration of antibody titers and potential for protection demonstrated in preclinical immunogenicity and challenge studies Vaccine candidate is stable at 2°C to 8°C and room temperature for at least 3 months and ongoing Preclinical studies and revised clinical plan to account for evolving regulatory landscape and emergence of new variants

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment Malcolm G. Witter to its Board of Directors. Mr. Witter brings decades of financial and corporate governance experience to the board. He currently serves as a corporate development leader for USI Insurance S

STRATA Skin Sciences, Inc. announced that it has renewed its existing debt with a lower interest one-year cash secured loan facility with Israel Discount Bank of New York, a multinational commercial bank.

Enzo Biochem, Inc. (NYSE:ENZ) (“Enzo” or “The Company”), a leading biosciences and diagnostics company, announced today that it has reviewed the position of Institutional Shareholder Services (“ISS”) regarding the Company’s executive compensation approach for the fiscal year ended July 31, 2020. To acknowledge and address the issues within the ISS report, Dr. Elazar Rabbani, the Company’s Chairperson and CEO, has requested the Compensation Commit

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced that it has received Bonsucro Chain of Custody Certification. Bonsucro is a global organization that p

Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that the underwriters of its public offering that closed on December 18, 2020, have exercised in full their option to

Gastric cancer (GC) is the second-leading cause of cancer-related mortality worldwide and is also responsible for a significantly high cancer burden, as measured by disability-adjusted life years lost.